Rezolute to Participate in Upcoming Investor Conferences
Investors can book one-on-one meetings and join management’s fireside chats with Rezolute at Cantor, H.C. Wainwright and Morgan Stanley in September 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rezolute (RZLT) will participate in three upcoming investor conferences in September 2026, including events hosted by Cantor, H.C. Wainwright, and Morgan Stanley. Management will take part in fireside chats and one-on-one investor meetings during these conferences and invites interested investors to schedule meetings through the respective bank representatives.
Details
News Market Reaction – RZLT
On Sep 2, the day this news came out, RZLT closed 1.67% above the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Event: Cantor Global Healthcare Conference
Date: September 9-11, 2026
Event: H.C. Wainwright 28th Annual Global Investment Conference
Date: September 14-16, 2026
Event: Morgan Stanley 24th Annual Global Healthcare Conference
Date: September 14-16, 2026
Management will be participating in fireside chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Cantor, H.C. Wainwright, and Morgan Stanley representatives.
About Rezolute, Inc.
Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.
Rezolute Contacts:
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim
cmckim@rezolutebio.com
336-608-9706
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Rezolute (RZLT) attend the Cantor Global Healthcare Conference?
Rezolute will participate in the Cantor Global Healthcare Conference from September 9-11, 2026. Company management plans to join fireside chats and hold one-on-one meetings with investors during the event.
What are the dates for Rezolute (RZLT) at the H.C. Wainwright 28th Annual Global Investment Conference?
Rezolute is scheduled to take part in the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, where management will engage in fireside chats and one-on-one investor meetings.
When is Rezolute (RZLT) participating in the Morgan Stanley 24th Annual Global Healthcare Conference?
Rezolute will participate in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026. Management will be available for fireside discussions and individual investor meetings throughout the conference.
How can investors schedule one-on-one meetings with Rezolute (RZLT) during these conferences?
Investors interested in meeting Rezolute’s management during the September 2026 conferences should contact their Cantor, H.C. Wainwright, or Morgan Stanley representatives to arrange one-on-one investor meetings.
What does Rezolute (RZLT) focus on in its biopharmaceutical business?
Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by congenital or acquired forms of hyperinsulinism (HI). Its antibody therapy, ersodetug, has been studied in clinical trials and used in real-world HI cases.